Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
Shiva Madhwan NairGencay HatibogluJames RelleKhalil HetouJason HafronChristopher HarleZahra KassamRobert StaruchMathieu BurtnykDavid BonekampHeinz-Peter SchlemmerMatthias C RoethkeMaya Mueller-WolfSascha PahernikJoseph L ChinPublished in: BJU international (2020)
With 3-year Phase I follow-up, TULSA demonstrates safe and precise ablation for men with localised prostate cancer, providing predictable PSA and biopsy outcomes, without affecting functional abilities or precluding salvage therapy.